Last updated on February 2018

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Brief description of study

  1. Objectives
    1. Which organ and how does SGLT2 inhibitor alter insulin sensitivity?
    2. How does SGLT2 inhibitor increase glucagon levels and hepatic glucose production?

Detailed Study Description

2. Clinical hypothesis

  1. SGLT2 inhibitor ameliorates fatty liver and obesity.
  2. SGLT2 inhibitor stimulates sympathetic activity.
  3. SGLT2 inhibitor increases glucagon secretion.
  4. SGLT2 inhibitor enhances lipolysis and hepatic glucose production.

Clinical Study Identifier: NCT02649465

Contact Investigators or Research Sites near you

Start Over

Yumie Takeshita, MD, PhD

Department of Disease Control and Homeostasis, Kanazawa University Hospital
Kanazawa, Japan
  Connect »